RCC adjuvant pembroluzimab benefit estimation for 5y OS - Evidencio
RCC adjuvant pembroluzimab benefit estimation for 5y OS

This tool estimates the 5-year survival benefit of 1-year adjuvant anti-PD1 treatment after surgical R0 resection for clear-cell renal cell carcinoma (ccRCC). The calculation uses the average death-rate per year of any cause in The Netherlands (CBS), the cancer-specific survival based on the Leibovich score (2018 version) and the hazard ratio (HR) for adjuvant anti-PD1 therapy based on the KN-564 study.

Sex is only relevant for the death-of-any-cause estimation, not for adjustment of the KN-564 HR. The HR can be adjusted for WHO ECOG performance, based on the KN-564 findings: without ECOG input the model uses 0.62, for ECOG-1 0.82 and for ECOG-0 0.55. The 10y survival prediction is for consultation without adjuvant therapy only, as current HR can not be extrapolated that far in the future.

Research authors: None
Version: 2.0
  • Public
  • Oncology
  • {{ modelType }}
  • Details
  • Validate algorithm
  • Save input
  • Load input
Display
Units

{{section.title}}

Calculate the result

Set more parameters to perform the calculation

Out of a 100 treated patients, Patients will survive anyhow for 5 years or more

{{ resultSubheader }}
{{ chart.title }}
Result interval {{ additionalResult.min }} to {{ additionalResult.max }}

Conditional information

Please don't forget to counsel your patient for participation in the PRO-RCC national cohort!

{{ file.classification }}
PRO
Note
Notes are only visible in the result download and will not be saved by Evidencio

This algorithm is provided for educational, training and information purposes. It must not be used to support medical decision making, or to provide medical or diagnostic services. Read our full disclaimer.

Underlying algorithms Part of
Comments
Comment
Please enter a comment
Comments are visible to anyone

Algorithm feedback

No feedback yet 1 Comment {{ model.comments.length }} Comments
On {{ comment.created_at }} {{ comment.user.username }} a no longer registered author wrote:
{{ comment.content }}
logo

Please sign in to enable Evidencio print features

In order to use the Evidencio print features, you need to be logged in.
If you don't have an Evidencio Community Account you can create your free personal account at:

https://www.evidencio.com/registration

Printed results - Examples {{ new Date().toLocaleString() }}


Evidencio Community Account Benefits


With an Evidencio Community account you can:

  • Create and publish your own prediction algorithms.
  • Share your prediction algorithms with your colleagues, research group, organization or the world.
  • Review and provide feedback on algorithms that have been shared with you.
  • Validate your algorithms and validate algorithms from other users.
  • Find algorithms based on Title, Keyword, Author, Institute, or MeSH classification.
  • Use and save prediction algorithms and their data.
  • Use patient specific protocols and guidelines based on sequential algorithms and decision trees.
  • Stay up-to-date with new algorithms in your field as they are published.
  • Create your own lists of favorite algorithms and topics.

A personal Evidencio account is free, with no strings attached!
Join us and help create clarity, transparency, and efficiency in the creation, validation, and use of medical prediction algorithms.


Disclaimer: Calculations alone should never dictate patient care, and are no substitute for professional judgement.
Evidencio v3.35 © 2015 - 2025 Evidencio. All Rights Reserved